Division of Radiotherapy, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
Nutrients. 2021 Apr 13;13(4):1277. doi: 10.3390/nu13041277.
The Prognostic Nutritional Index (PNI) is a parameter of nutritional and inflammation status related to toxicity in cancer treatment. Since data for head and neck cancer are scanty, this study aims to investigate the association between PNI and acute and late toxicity for this malignancy.
A retrospective cohort of 179 head and neck cancer patients treated with definitive radiotherapy with induction/concurrent chemotherapy was followed-up (median follow-up: 38 months) for toxicity and vital status between 2010 and 2017. PNI was calculated according to Onodera formula and low/high PNI levels were defined according to median value. Odds ratio (OR) for acute toxicity were calculated through logistic regression model; hazard ratios (HR) for late toxicity and survival were calculated through the Cox proportional hazards model.
median PNI was 50.0 (interquartile range: 45.5-53.5). Low PNI was associated with higher risk of weight loss > 10% during treatment (OR = 4.84, 95% CI: 1.73-13.53 for PNI < 50 versus PNI ≥ 50), which was in turn significantly associated with worse overall survival, and higher risk of late mucositis (HR = 1.84; 95% CI:1.09-3.12). PNI predicts acute weight loss >10% and late mucositis.
PNI could help clinicians to identify patients undergoing radiotherapy who are at high risk of acute and late toxicity.
预后营养指数(PNI)是与癌症治疗中毒性相关的营养和炎症状态的参数。由于头颈部癌症的数据有限,本研究旨在调查 PNI 与这种恶性肿瘤的急性和晚期毒性之间的关系。
回顾性队列研究了 179 例接受根治性放疗联合诱导/同期化疗的头颈部癌症患者(中位随访时间:38 个月),随访时间为 2010 年至 2017 年,随访内容包括毒性和生存情况。根据小野寺公式计算 PNI,并根据中位数将 PNI 分为低/高水平。通过逻辑回归模型计算急性毒性的优势比(OR);通过 Cox 比例风险模型计算晚期毒性和生存的风险比(HR)。
中位 PNI 为 50.0(四分位距:45.5-53.5)。低 PNI 与治疗期间体重减轻>10%的风险增加相关(OR=4.84,95%CI:PNI<50 与 PNI≥50 相比,1.73-13.53),这与总生存较差显著相关,并且与晚期黏膜炎的风险增加相关(HR=1.84;95%CI:1.09-3.12)。PNI 预测急性体重减轻>10%和晚期黏膜炎。
PNI 可以帮助临床医生识别接受放疗的患者中具有高急性和晚期毒性风险的患者。